{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:41:43Z","timestamp":1793954503645,"version":"4.8.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP2HL152427"],"award-info":[{"award-number":["DP2HL152427"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["U19NS132301"],"award-info":[{"award-number":["U19NS132301"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtm.2025.101599","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T06:14:46Z","timestamp":1758953686000},"page":"101599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systemic mRNA-LNP administration in fetuses improves survival in a mouse model of spinal muscular atrophy"],"prefix":"10.1016","volume":"33","author":[{"given":"Marco D.","family":"Carpenter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa B.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooda","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Dumitru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson H.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Luks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriya","family":"Teerdhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarsha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Zoltick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad G.","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Peranteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101599_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41525-020-00155-8","article-title":"Measurement of genetic diseases as a cause of mortality in infants receiving whole genome sequencing","volume":"5","author":"Kingsmore","year":"2020","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.omtm.2025.101599_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Sighn","year":"2017","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"10.1016\/j.omtm.2025.101599_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101599_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101599_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101599_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2025.101599_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2025.101599_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/NEN.0b013e3181a10ea1","article-title":"The Developmental Pattern of Myotubes in Spinal Muscular Atrophy Indicates Prenatal Delay of Muscle Maturation","volume":"68","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtm.2025.101599_bib9","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/brain\/awf155","article-title":"Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord","volume":"125","author":"Soler-Botija","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.omtm.2025.101599_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/(SICI)1097-0223(199702)17:2<166::AID-PD14>3.0.CO;2-D","article-title":"SONOGRAPHIC AND MATERNAL SERUM SCREENING ABNORMALITIES IN FETUSES AFFECTED BY SPINAL MUSCULAR ATROPHY","volume":"17","author":"Rijhsinghani","year":"1997","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.omtm.2025.101599_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101599_bib12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2025.101599_bib13","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/v15091801","article-title":"Innate Immune Response to Viral Vectors in Gene Therapy","volume":"15","author":"Wang","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2025.101599_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/ph17030394","article-title":"Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma\u00ae) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtm.2025.101599_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/science.adg6518","article-title":"Base editing rescue of spinal muscular atrophy in cells and in mice","volume":"380","author":"Arbab","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101599_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-023-01132-z","article-title":"Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy","volume":"8","author":"Alves","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtm.2025.101599_bib17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41422-020-0304-y","article-title":"Base editing-mediated splicing correction therapy for spinal muscular atrophy","volume":"30","author":"Lin","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.omtm.2025.101599_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/brainsci11030367","article-title":"Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients","volume":"11","author":"Osmanovic","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.omtm.2025.101599_bib19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2025.101599_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv4656","article-title":"Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy","volume":"17","author":"Borges","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101599_bib21","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41467-025-57446-w","article-title":"Monitoring mRNA vaccine antigen expression in vivo using PET\/CT","volume":"16","author":"Blizard","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101599_bib22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1021\/acs.nanolett.3c03509","article-title":"Predictive High-Throughput Platform for Dual Screening of mRNA Lipid Nanoparticle Blood\u2013Brain Barrier Transfection and Crossing","volume":"24","author":"Han","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtm.2025.101599_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114861","article-title":"Lipid nanoparticle-mediated drug delivery to the brain","volume":"197","author":"Khare","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtm.2025.101599_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtm.2025.101599_bib25","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41467-023-39246-2","article-title":"Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing","volume":"14","author":"Brooks","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101599_bib26","doi-asserted-by":"crossref","first-page":"13594","DOI":"10.1021\/acsnano.3c02268","article-title":"Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease","volume":"17","author":"Palanki","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtm.2025.101599_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","author":"Carrasco","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtm.2025.101599_bib28","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1038\/s41467-022-35384-1","article-title":"Cell-type specific profiling of histone post-translational modifications in the adult mouse striatum","volume":"13","author":"Carpenter","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101599_bib29","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1126\/science.aay0793","article-title":"Brain cell type\u2013specific enhancer\u2013promoter interactome maps and disease - risk association","volume":"366","author":"Nott","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101599_bib30","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.3390\/ijms22105335","article-title":"INTACT vs. FANS for Cell-Type-Specific Nuclei Sorting: A Comprehensive Qualitative and Quantitative Comparison","volume":"22","author":"Chongtham","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101599_bib31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41374-021-00698-z","article-title":"A method for rapid flow-cytometric isolation of endothelial nuclei and RNA from archived frozen brain tissue","volume":"102","author":"Kimble","year":"2022","journal-title":"Lab. Invest."},{"key":"10.1016\/j.omtm.2025.101599_bib32","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1007\/s12274-024-6827-7","article-title":"Lipid nanoparticles deliver mRNA to the blood\u2013brain barrier","volume":"17","author":"Kuzminich","year":"2024","journal-title":"Nano Res."},{"key":"10.1016\/j.omtm.2025.101599_bib33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","article-title":"Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101599_bib34","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1042\/BST20221508","article-title":"Unlocking the secrets of ABEs: the molecular mechanism behind their specificity","volume":"51","author":"Chen","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.omtm.2025.101599_bib35","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101599_bib36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2025.101599_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2025.101599_bib38","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.omtm.2025.101599_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41563-023-01481-9","article-title":"P-selectin-targeted nanocarriers induce active crossing of the blood\u2013brain barrier via caveolin-1-dependent transcytosis","volume":"22","author":"Tylawsky","year":"2023","journal-title":"Nat. Mater."},{"key":"10.1016\/j.omtm.2025.101599_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032568","article-title":"Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model","volume":"7","author":"Wagner","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101599_bib41","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1073\/pnas.1912012117","article-title":"Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood\u2013brain barrier","volume":"117","author":"Marcos-Contreras","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101599_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2012.00046","article-title":"Barrier Mechanisms in the Developing Brain","volume":"3","author":"Saunders","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtm.2025.101599_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2014.00404","article-title":"The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history","volume":"8","author":"Saunders","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtm.2025.101599_bib44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature13324","article-title":"Mfsd2a is critical for the formation and function of the blood\u2013brain barrier","volume":"509","author":"Ben-Zvi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101599_bib45","article-title":"Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain","volume":"2","author":"Rungta","year":"2013","journal-title":"Mol. Ther. Acids"},{"key":"10.1016\/j.omtm.2025.101599_bib46","article-title":"A Bioinspired Platform for Effective Delivery of Protein Therapeutics to the Central Nervous System","volume":"31","author":"Wu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtm.2025.101599_bib47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1039\/D3NA00699A","article-title":"Ionic liquid-coated lipid nanoparticles increase siRNA uptake into CNS targets","volume":"6","author":"Khare","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.omtm.2025.101599_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1208\/s12248-021-00653-2","article-title":"Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells","volume":"24","author":"Khare","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.omtm.2025.101599_bib49","doi-asserted-by":"crossref","first-page":"14957","DOI":"10.1002\/anie.202004994","article-title":"Protein and mRNA Delivery Enabled by Cholesteryl-Based Biodegradable Lipidoid Nanoparticles","volume":"59","author":"Li","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.omtm.2025.101599_bib50","article-title":"Microglial Dynamics, Blood-Brain Barrier Morphogenesis, and Developmental Toxicity: a brief review and computational model","volume":"36","author":"Naphade","year":"2023","journal-title":"Curr. Opin. Toxicol."},{"key":"10.1016\/j.omtm.2025.101599_bib51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41593-023-01312-9","article-title":"Profiling spatiotemporal gene expression of the developing human spinal cord and implications for ependymoma origin","volume":"26","author":"Li","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2025.101599_bib52","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.STR.7.6.560","article-title":"Comparison of vascular reactivity in spinal cord and brain","volume":"7","author":"Nix","year":"1976","journal-title":"Stroke"},{"key":"10.1016\/j.omtm.2025.101599_bib53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejpb.2016.10.016","article-title":"Applications of lipid nanoparticles in gene therapy","volume":"109","author":"Del Pozo-Rodr\u00edguez","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.omtm.2025.101599_bib54","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tips.2021.03.002","article-title":"The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA","volume":"42","author":"Patel","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtm.2025.101599_bib55","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/acs.accounts.9b00177","article-title":"Carriers Break Barriers in Drug Delivery: Endocytosis and Endosomal Escape of Gene Delivery Vectors","volume":"52","author":"Degors","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtm.2025.101599_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial Delivery Systems for mRNA Vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.omtm.2025.101599_bib57","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2025.101599_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113945","article-title":"Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection","volume":"384","author":"Ren","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtm.2025.101599_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-42522-1","article-title":"Placental secretion of apolipoprotein A1 and E: the anti-atherogenic impact of the placenta","volume":"9","author":"Melhem","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2025.101599_bib60","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41563-024-02114-5","article-title":"Blood\u2013brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.omtm.2025.101599_bib61","series-title":"Newborn Screening for 5q-Linked Spinal Muscular Atrophy: IQWiG Reports \u2013 Commission No. S18-02","year":"2020"},{"key":"10.1016\/j.omtm.2025.101599_bib62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2025.101599_bib63","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMc2300802","article-title":"Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy","volume":"392","author":"Finkel","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101599_bib64","doi-asserted-by":"crossref","first-page":"8703","DOI":"10.1523\/JNEUROSCI.0204-12.2012","article-title":"Survival Motor Neuron Protein in Motor Neurons Determines Synaptic Integrity in Spinal Muscular Atrophy","volume":"32","author":"Martinez","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.omtm.2025.101599_bib65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1101\/gad.256644.114","article-title":"Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models","volume":"29","author":"Hua","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtm.2025.101599_bib66","doi-asserted-by":"crossref","first-page":"E5863","DOI":"10.1073\/pnas.1509758112","article-title":"Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II\/III spinal muscular atrophy","volume":"112","author":"Bogdanik","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101599_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105444","article-title":"Liver SMN restoration rescues the Smn2B\/- mouse model of spinal muscular atrophy","volume":"110","author":"Sutton","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtm.2025.101599_bib68","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1093\/hmg\/ddv283","article-title":"SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMN\u03947 mouse model of SMA","volume":"24","author":"McGovern","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101599_bib69","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose\u2013response Study in Mice and Nonhuman Primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101599_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202417097","article-title":"Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous System Upon Intrathecal Injection","volume":"37","author":"Xue","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtm.2025.101599_bib71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.11.022","article-title":"Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.omtm.2025.101599_bib72","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2025.101599_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav8375","article-title":"In utero gene editing for monogenic lung disease","volume":"11","author":"Alapati","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101599_bib74","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1038\/s41467-021-24443-8","article-title":"In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease","volume":"12","author":"Bose","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:31:08Z","timestamp":1776198668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2329050125001949"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101599","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic mRNA-LNP administration in fetuses improves survival in a mouse model of spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101599"}}